Home Hepatitis Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain

Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain

Credits to the Source Link Daniel
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain
  • 1.

    World Health Organization. Global hepatitis report, 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1 (2017).

  • 2.

    Borgia, S. M. et al. Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J. Infect. Dis. 218, 1722–1729 (2018).

    PubMed 

    Google Scholar
     

  • 3.

    Smith, D. B. et al. International Committee on Taxonomy of Viruses (ICTV). HCV classification. A web resource to manage the classification and genotype and subtype assignments of hepatitis C virus. https://talk.ictvonline.org/ictv_wikis/flaviviridae/w/sg_flavi/56/hcv-classification.

  • 4.

    Blach, S. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2, 161–176 (2017).


    Google Scholar
     

  • 5.

    McNaughton, A. L. et al. Spatiotemporal reconstruction of the introduction of hepatitis C virus into Scotland and its subsequent regional transmission. J. Virol. 89, 11223–11232 (2015).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 6.

    Acero Fernández, D. et al. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol. Hepatol. 41, 2–11 (2018).

    PubMed 

    Google Scholar
     

  • 7.

    Berenguer, J. et al. Human immunodeficiency virus/hepatits C virus coinfection in Spain: elimination is feasible, but the burden of residual cirrhosis will be significant. Open Forum Infect. Dis. 5, 1–8 (2018).


    Google Scholar
     

  • 8.

    Zeuzem, S. et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J. Hepatol. 66, 910–918 (2017).

    CAS 
    PubMed 

    Google Scholar
     

  • 9.

    Lavin, A. C. et al. Prevalence of hepatitis C in the Spanish population: the prevhep study (ethon cohort). J. Hepatol. 66, S272 (2017).


    Google Scholar
     

  • 10.

    García-Fulgueiras, A. et al. Hepatitis C and hepatitis B-related mortality in Spain. Eur. J. Gastroenterol. Hepatol. 21, 895–901 (2009).

    PubMed 

    Google Scholar
     

  • 11.

    Aguilera, A. et al. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000–2015 period (the GEHEP 005 study). J. Viral Hepat. 24, 725–732 (2017).

    CAS 
    PubMed 

    Google Scholar
     

  • 12.

    Secretaría General de Sanidad y Consumo Ministerio de Sanidad, Consumo y Bienestar Social. Plan Estratégico para el Abordaje de la Hepatitis C en el Sistema Nacional de Salud (PEAHC) (2018). https://doi.org/10.1016/j.ceramint.2013.10.089.

  • 13.

    Palladino, C. et al. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Sci. Rep. 7, 3–8 (2017).


    Google Scholar
     

  • 14.

    von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int. J. Surg. 61, 344–349 (2014).


    Google Scholar
     

  • 15.

    Abbott Molecular Inc. Abbott RealTime HCV Genotype II (2013).

  • 16.

    Leitner, T. et al. Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 15, 120–127 (1993).

    CAS 
    PubMed 

    Google Scholar
     

  • 17.

    Struck, D., Lawyer, G., Ternes, A. M., Schmit, J. C. & Bercoff, D. P. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 42, 1–11 (2014).


    Google Scholar
     

  • 18.

    Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772–780 (2013).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 19.

    Kumar, S., Stecher, G. & Tamura, K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol. Biol. Evol. 33, 1870–1874 (2016).

    CAS 

    Google Scholar
     

  • 20.

    Silvestro, D. & Michalak, I. raxmlGUI: a graphical front-end for RAxML. Org. Divers. Evol. 12, 335–337 (2012).


    Google Scholar
     

  • 21.

    Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v4: recent updates and new developments. Nucleic Acids Res. 47, W256–W259 (2019).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 22.

    Ragonnet-Cronin, M. et al. Automated analysis of phylogenetic clusters. BMC Bioinform. 14, 317 (2013).


    Google Scholar
     

  • 23.

    Drummond, A. J., Suchard, M. A., Xie, D. & Rambaut, A. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol. Biol. Evol. 29, 1969–1973 (2012).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 24.

    Nguyen, L.-T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol. Biol. Evol. 32, 268–274 (2015).

    CAS 

    Google Scholar
     

  • 25.

    Rambaut, A., Lam, T. T., Carvalho, L. M. & Pybus, O. G. Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen). Virus Evol. 2, 1–7 (2016).


    Google Scholar
     

  • 26.

    Palladino, C. et al. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci. Rep. 8, 12266 (2018).

    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 27.

    Shapiro, B., Rambaut, A. & Drummond, A. J. Choosing appropriate substitution models for the phylogenetic analysis of protein-coding sequences. Mol. Biol. Evol. 23, 7–9 (2006).

    CAS 
    PubMed 

    Google Scholar
     

  • 28.

    Iles, J. C. et al. Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa. Virology 464–465, 233–243 (2014).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 29.

    Pybus, O. G. et al. Genetic history of hepatitis C virus in East Asia. J. Virol. 83, 1071–1082 (2009).

    CAS 
    PubMed 

    Google Scholar
     

  • 30.

    Pybus, O. G., Drummond, A. J., Nakano, T., Robertson, B. H. & Rambaut, A. The epidemiology and iatrogenic transmission of hepatitis C virus in egypt: A Bayesian coalescent approach. Mol. Biol. Evol. 20, 381–387 (2003).

    CAS 
    PubMed 

    Google Scholar
     

  • 31.

    Gray, R. R. et al. The mode and tempo of hepatitis C virus evolution within and among hosts. BMC Evol. Biol. 11, 131 (2011).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 32.

    Xie, W., Lewis, P. O., Fan, Y., Kuo, L. & Chen, M.-H. Improving marginal likelihood estimation for Bayesian phylogenetic model selection. Syst. Biol. 60, 150–160 (2011).

    PubMed 

    Google Scholar
     

  • 33.

    Kass, R. E. & Raftery, A. E. Bayes factors. J. Am. Stat. Assoc. 90, 773–795 (1995).

    MathSciNet 
    MATH 

    Google Scholar
     

  • 34.

    Bielejec, F. et al. SpreaD3: interactive visualization of spatiotemporal history and trait evolutionary processes. Mol. Biol. Evol. 33, 2167–2169 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 35.

    Tableau. https://www.tableau.com/. https://www.webcitation.org/6w4yCTPjb. Accessed 1 Oct 2018.

  • 36.

    Pawlotsky, J.-M. et al. EASL recommendations on treatment of hepatitis C 2018. J. Hepatol. 69, 461–511 (2018).


    Google Scholar
     

  • 37.

    AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin. Infect. Dis. 67, 1477–1492 (2018).


    Google Scholar
     

  • 38.

    Wyles, D. L. & Luetkemeyer, A. F. Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens. Top Antivir. Med. 25, 103 (2017).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 39.

    Pickett, B. E., Striker, R. & Lefkowitz, E. J. Evidence for separation of HCV subtype 1a into two distinct clades. J. Viral Hepat. 18, 608–618 (2011).

    CAS 
    PubMed 

    Google Scholar
     

  • 40.

    De Luca, A. et al. Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors. Open Forum Infect. Dis. 2, ofv043 (2015).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 41.

    Id, G. S. et al. Hepatitis C virus genetic diversity by geographic region within genotype 1–6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS ONE 13, e0205186 (2018).


    Google Scholar
     

  • 42.

    Jimenez-Sousa, M. A. et al. NS3 Resistance-Associated Variants (RAVs) in patients infected with HCV genotype 1a in Spain. PLoS ONE 11, e0163197 (2016).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 43.

    Bradshaw, D., Matthews, G. & Danta, M. Sexually transmitted hepatitis C infection: the new epidemic in MSM?. Curr. Opin. Infect. Dis. 26, 66–72 (2013).

    CAS 
    PubMed 

    Google Scholar
     

  • 44.

    Parikh, N. et al. Substance Abuse, HIV-1 and Hepatitis. Curr. HIV Res. 10, 557–571 (2012).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 45.

    Bagaglio, S. et al. Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients. Clin. Microbiol. Infect. 22(386), e1-386.e3 (2016).


    Google Scholar
     

  • 46.

    Bae, A. et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob. Agents Chemother. 54, 5288–5297 (2010).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 47.

    Asselah, T. & Marcellin, P. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int. 34, 60–68 (2014).

    CAS 
    PubMed 

    Google Scholar
     

  • 48.

    Wiktor, S., Ford, N., Ball, A. & Hirnschall, G. HIV and HCV: distinct infections with important overlapping challenges. J. Int. AIDS Soc. 17, 1–2 (2014).


    Google Scholar
     

  • 49.

    Lissen, E., Wichmann, I., Jimenez, J. M. & Andreu-Kern, F. AIDS in haemophilia patients in Spain. Lancet 321, 992–993 (1983).


    Google Scholar
     

  • 50.

    Estruch, R. et al. Acquired immunodeficiency syndrome in a male residing in Barcelona. Med Clin 81, 645 (1983).

    CAS 

    Google Scholar
     

  • 51.

    Sistema de información sobre nuevos diagnósticos de VIH. Registro nacional de casos de SIDA. Ministerio de Sanidad Servicios Sociales e Igualdad. Vigilancia Epidemiológica del VIH y SIDA en España 2017. Actualización 30 de junio de 2018. 1–43 (2018).

  • 52.

    Wiessing, L. et al. Hepatitis C virus infection epidemiology among people who inject drugs in europe: a systematic review of data for scaling up treatment and prevention. PLoS ONE 9, e103345 (2014).

    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 53.

    Serra, M. A., Rodríguez, F., Del Olmo, J. A., Escudero, A. & Rodrigo, J. M. Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage. J. Viral Hepat. 10, 183–188 (2003).

    CAS 
    PubMed 

    Google Scholar
     

  • 54.

    Touceda, S., Pereira, M. & Agulla, A. Prevalence of hepatitis C virus genotypes in the area of El Ferrol (La Coruña, Spain). Enferm. Infecc. Microbiol. Clin. 20, 200–204 (2002).

    PubMed 

    Google Scholar
     

  • 55.

    Rial-Crestelo, D. et al. Effectiveness of direct-acting antiviral therapy in patients with a HCV/HIV coinfection: a multicenter cohort study. Rev. Esp. Enfermedades Dig. 110, 35–42 (2018).

    CAS 

    Google Scholar
     

  • 56.

    Acero Fernández, D. et al. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol. Hepatol. 41, 2–11 (2018).

    PubMed 

    Google Scholar
     

  • 57.

    Malta, F. et al. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. BMC Infect. Dis. 17, 1–6 (2017).


    Google Scholar
     

  • 58.

    Carrasco, I. et al. Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients. J. Med. Virol. 90, 532–536 (2017).

    PubMed 

    Google Scholar
     

  • 59.

    Grandal, M. et al. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies. J. Med. Virol. 90, 1094–1098 (2018).

    CAS 
    PubMed 

    Google Scholar
     

  • 60.

    Wang, G. P. et al. Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci. Rep. 8, 1–14 (2018).

    ADS 

    Google Scholar
     

  • 61.

    Organización Médica Colegial de España. Día Mundial de la Hepatitis. (2018).

  • 62.

    Parker, C. M., Hirsch, J. S., Hansen, H. B., Branas, C. & Martins, S. S. Facing opioids in the shadow of the HIV epidemic. N. Engl. J. Med. 380, 1–3 (2019).

    PubMed 

    Google Scholar
     

  • 63.

    Konerman, M. A. & Lok, A. S. F. Hepatitis C treatment and barriers to eradication. Clin. Transl. Gastroenterol. 7, e193–e196 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Source Link

    Related Articles

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: